Heart failure (HF) with preserved ejection fraction (HFpEF) is a common disease affecting the elderly in particular. Up to 80% of these patients develop pulmonary hypertension (PH), which is associated with worse symptoms and increased mortality.1 It is a matter of concern that drugs approved for pulmonary arterial hypertension (PAH) are sometimes used in such patients despite insufficient data for their safety and efficacy. On the other hand, the impact of PH and right ventricular (RV) dysfunction on morbidity and mortality in HFpEF call for proper attention both at the clinical and scientific level. Here we discuss the clinical problem, pathophysiology, diagnostic shortfalls, gaps in evidence, and future strategies for PH-HFpEF

Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research† / Hoeper, Marius M; Lam, Carolyn S. P; Vachiery, Jean Luc; Bauersachs, Johann; Gerges, Christian; Lang, Irene M; Bonderman, Diana; Olsson, Karen M; Gibbs, J. Simon R; Dorfmuller, Peter; Guazzi, Marco; Galie', Nazzareno; Manes, Alessandra; Handoko, M. Louis; Vonk Noordegraaf, Anton; Lankeit, Mareike; Konstantinides, Stavros; Wachter, Rolf; Opitz, Christian; Rosenkranz, Stephan. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - STAMPA. - 38:38(2017), pp. 2869-2873. [10.1093/eurheartj/ehw597]

Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research†

Galie', Nazzareno;Manes, Alessandra;
2017

Abstract

Heart failure (HF) with preserved ejection fraction (HFpEF) is a common disease affecting the elderly in particular. Up to 80% of these patients develop pulmonary hypertension (PH), which is associated with worse symptoms and increased mortality.1 It is a matter of concern that drugs approved for pulmonary arterial hypertension (PAH) are sometimes used in such patients despite insufficient data for their safety and efficacy. On the other hand, the impact of PH and right ventricular (RV) dysfunction on morbidity and mortality in HFpEF call for proper attention both at the clinical and scientific level. Here we discuss the clinical problem, pathophysiology, diagnostic shortfalls, gaps in evidence, and future strategies for PH-HFpEF
2017
Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research† / Hoeper, Marius M; Lam, Carolyn S. P; Vachiery, Jean Luc; Bauersachs, Johann; Gerges, Christian; Lang, Irene M; Bonderman, Diana; Olsson, Karen M; Gibbs, J. Simon R; Dorfmuller, Peter; Guazzi, Marco; Galie', Nazzareno; Manes, Alessandra; Handoko, M. Louis; Vonk Noordegraaf, Anton; Lankeit, Mareike; Konstantinides, Stavros; Wachter, Rolf; Opitz, Christian; Rosenkranz, Stephan. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - STAMPA. - 38:38(2017), pp. 2869-2873. [10.1093/eurheartj/ehw597]
Hoeper, Marius M; Lam, Carolyn S. P; Vachiery, Jean Luc; Bauersachs, Johann; Gerges, Christian; Lang, Irene M; Bonderman, Diana; Olsson, Karen M; Gibbs, J. Simon R; Dorfmuller, Peter; Guazzi, Marco; Galie', Nazzareno; Manes, Alessandra; Handoko, M. Louis; Vonk Noordegraaf, Anton; Lankeit, Mareike; Konstantinides, Stavros; Wachter, Rolf; Opitz, Christian; Rosenkranz, Stephan
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/589961
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 102
  • ???jsp.display-item.citation.isi??? 93
social impact